预约演示

更新于：2025-10-14

Bevacizumab

贝伐珠单抗

更新于：2025-10-14

概要

基本信息

药物类型

单克隆抗体

别名

Bevacizumab(Genetical Recombination)、rhuMAb-VEGF、贝伐单抗

+ [17]

靶点

VEGF-A

作用方式

抑制剂

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)、血管生成抑制剂

治疗领域

肿瘤神经系统疾病消化系统疾病+ [11]

在研适应症

不可切除的肝细胞癌肝细胞癌复发性胶质母细胞瘤+ [219]

非在研适应症

异戊酸血症急性嗜碱性粒细胞白血病急性嗜酸细胞白血病+ [281]

原研机构

Genentech, Inc.

在研机构

National Cancer InstituteRoche Registration GmbHHoffmann-La Roche, Inc.

+ [26]

非在研机构

Roswell Park Comprehensive Cancer Center

The University of California, San Francisco

Celgene Corp.

+ [53]

权益机构

Roche Korea Co., Ltd.

Immune-Onc Therapeutics, Inc.

Roche Holding AG

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2004-02-26),

结肠癌直肠癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 41632H

来源: *****

Sequence Code 41637L

来源: *****

关联

3,420

项与贝伐珠单抗相关的临床试验

NCT06971744

/ Not yet recruiting临床2期

Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial

This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.

开始日期2026-01-01

申办/合作机构

The Medical University of South Carolina

NCT07198074

/ Not yet recruiting临床3期IIT

A Randomized Phase II/III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.

开始日期2025-12-15

申办/合作机构

National Cancer Institute

NCT06264531

/ Not yet recruiting临床2/3期IIT

Evaluation of the Efficacy and Safety of Anti-angiogenic Therapy With Intravenous Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

Brain arteriovenous malformations (AVMs) are responsible for hemorrhagic strokes, particularly in children and young adults. They can also be responsible for chronic neurological disorders: motor or sensory deficits, disturbances of higher functions, epilepsy or disabling headaches. The management of brain AVMs is complex and requires a multidisciplinary approach in an expert center. Available therapies include endovascular embolization, neurosurgical resection and/or radiosurgery. These procedures carry a risk of neurological complications, and are reserved for small AVMs located at a distance from highly functional cerebral structures. To date, no drug therapy is recommended if interventional treatment is not possible.
Several studies on resected brain AVM tissue have demonstrated that these malformations are the site of significant evolutionary inflammatory and neo-angiogenesis processes. Other studies have specifically shown that VEGF (vascular endothelial growth factor) levels are increased in AVMs. More recently, a pre-clinical study showed that anti-angiogenic treatment with Bevacizumab reduced vascular proliferation within AVMs in mice. Finally, a Phase II clinical trial in patients with Rendu-Osler disease (a genetic vascular disorder characterized by recurrent epistaxis, cutaneous telangiectasia and the presence of visceral AVMs) showed a clinical benefit of IV Bevacizumab on the symptomatology of these vascular malformations, with a reduction in the risk of hemorrhage and the extent of hepatic arteriovenous shunts. A randomized Phase III trial is currently underway (NCT03227263) to assess the efficacy of IV Bevacizumab in Rendu-Osler disease.
The aim of our study is to assess the efficacy of IV Bevacizumab on the disabling symptoms associated with symptomatic brain AVMs.

开始日期2025-12-01

申办/合作机构

Fondation Ophtalmologique Adolphe de Rothschild

100 项与贝伐珠单抗相关的临床结果

登录后查看更多信息

100 项与贝伐珠单抗相关的转化医学

登录后查看更多信息

100 项与贝伐珠单抗相关的专利（医药）

登录后查看更多信息

22,449

项与贝伐珠单抗相关的文献（医药）

2026-04-01·DEN open

Long‐term results of palliative placement of very low‐axial force self‐expandable metallic stents for malignant colorectal obstruction

Article

作者: Moroi, Rintaro ; Kuwai, Toshio ; Yoshida, Shuntaro ; Enomoto, Toshiyuki ; Tomita, Masafumi ; Kyo, Rika ; Shiratori, Toshiyasu ; Saida, Yoshihisa ; Matsuzawa, Takeaki ; Isayama, Hiroyuki ; Sumida, Yorinobu ; Yamada, Tomonori ; Sasaki, Takashi

Abstract:

Objectives:

Stent placement is a standard option for palliative decompression in patients with malignant colorectal obstruction. Long‐term stent placement is associated with perforation, migration, and stent occlusion. Perforation is associated with life expectancy. Several studies have shown that stents with a high axial force (AF), which is defined as the force required to maintain the stent straight after it has bent, are associated with a higher perforation rate. Therefore, we evaluated the long‐term outcomes of using a very low AF stent (Niti‐S Enteral Colonic Uncovered stent D‐type) for palliative purposes.

Methods:

Eighty‐one consecutive patients with malignant colorectal obstruction in 33 medical institutions were evaluated. A stent with very low AF was placed using an endoscope system. We evaluated the adverse events (including perforation, migration, and stent occlusion), 1‐year survival rate, and cumulative patency rate. Univariate analysis was conducted using Fisher's exact test. The overall survival and cumulative patency rates were assessed using the Kaplan–Meier method.

Results:

The 1‐year cumulative survival rate was 37.8% after stent placement. The 3‐month, 6‐month, and 1‐year cumulative patency rates after stenting were 93.6%, 84.2%, and 75.8%, respectively. The major adverse events included stent migration (6.2%), stent occlusion (9.9%), and perforation (2.5%). Chemotherapy was administered in 26 cases (32.1%) after stenting, and bevacizumab was administered in five cases. However, no cases of perforation occurred following bevacizumab administration.

Conclusions:

Our results suggest that very low AF stents are safe and effective. Therefore, they may be a suitable option for applications, such as palliation. (UMIN 000011304)

2026-01-01·DRUG RESISTANCE UPDATES

Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis

Article

作者: Meng, Lin ; Shou, Chengchao ; Wang, Lixin ; Liu, Caiyun ; Qu, Like ; Dong, Bin ; Zhao, Chuanke

BACKGROUND:

Resistance to Bevacizumab (Bev) remains a major obstacle in colorectal cancer (CRC) treatment. Gamma-synuclein (SNCG), overexpressed in tumor vasculature and cancer cells, is investigated here for its role in Bev resistance and therapeutic potential.

METHODS:

Using isogenic CRC models with SNCG overexpression or knockout, we assessed SNCG's impact on Bev response in vitro and in vivo. The therapeutic efficacy of combining Bev with an anti-SNCG monoclonal antibody (42#) was evaluated in Bev-resistant models. Mechanistic studies, including ELISA, Western blot, surface plasmon resonance (SPR), and molecular docking, explored interactions between SNCG, VEGF, and VEGFR2.

RESULTS:

SNCG overexpression reduced Bev sensitivity by impairing the inhibition of migration, invasion, and spheroid formation, whereas SNCG knockout enhanced therapeutic response. Molecular docking revealed that SNCG binds VEGFR2 at an allosteric site, forming a stable ternary complex (SNCG-VEGF-VEGFR2) with enhanced hydrogen bonding, which sustained VEGFR2 phosphorylation and angiogenesis. In vivo, SNCG-overexpressing tumors showed reduced responsiveness to Bev (42.8 % inhibition vs. 64.3 % in controls, p < 0.05), while SNCG-deficient tumors exhibited a 3.2-fold increase in sensitivity. Combining Bev with 42# synergistically suppressed tumor growth (0.70 ± 0.36 g vs. 1.55 ± 0.41 g, p = 0.003), reduced metastatic burden (0.29 ± 0.23 g vs. 0.97 ± 0.42 g, p = 0.006), and extended median survival (86.8 vs. 69.8 days, p = 0.033) in Bev-resistant models.

CONCLUSIONS:

SNCG drives Bev resistance in CRC by forming a ternary complex with VEGF and VEGFR2, enhancing VEGFR2 signaling and angiogenesis. Dual targeting of VEGF and SNCG represents a promising therapeutic strategy to overcome Bev resistance, with the potential to improve outcomes in CRC patients.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer

Article

作者: Appukkuttan, Sreevalsa ; Cho, Sang Kyu ; Barzi, Afsaneh ; Grossman, Jamie ; Lee, Woojung ; Babajanyan, Svetlana ; Hocum, Brian ; Marian, Marisca ; Yang, Min ; Bekaii-Saab, Tanios

BACKGROUND:

New regimens have emerged as third-line or later therapies for metastatic colorectal cancer (mCRC), including regorafenib dose optimization (ReDO), trifluridine/tipiracil and bevacizumab (TAS-BEV) combination therapy, and fruquintinib. We evaluated relative cost-effectiveness of these therapies in patients with mCRC from a US payer's perspective.

MATERIALS AND METHODS:

A partitioned survival model (PSM) was constructed to estimate total costs and quality-adjusted life years (QALYs). Clinical parameters were obtained from pivotal trials of the respective therapies and incremental cost-effectiveness ratios (ICERs) were estimated to assess relative cost-effectiveness of these treatments. Model robustness was assessed using deterministic (DSA) and probabilistic sensitivity analysis (PSA). Three scenario analyses were conducted: (1) assuming equal efficacy across treatments, (2) with prior exposure to anti-vascular endothelial growth factor (VEGF) therapy, and (3) alternative clinical inputs for fruquintinib from a different clinical trial.

RESULTS:

Under the conventional willingness-to-pay (WTP) threshold in US ($150,000 per QALY gained), ReDO was cost-effective when compared with TAS-BEV and was dominant over fruquintinib. TAS-BEV was associated with an incremental QALY of 0.197 over ReDO, resulting in an ICER at $554,567 per QALY gained. The base case results were robust in DSA and PSA. Most influential parameters were treatment cost and effectiveness. In patients with prior anti-VEGF therapy, ReDO remained cost-effective compared to TAS-BEV and fruquintinib under the conventional WTP threshold.

LIMITATION:

Differences in trial populations may affect the comparability of the outcomes. Sensitivity and scenario analyses were conducted to address these limitations.

CONCLUSION:

ReDO was cost-effective compared with TAS-BEV from the US payer's perspective despite a higher QALY gain associated with TAS-BEV. ReDO was dominant over fruquintinib, consistently having a higher QALY gain and lower cost.

3,064

项与贝伐珠单抗相关的新闻（医药）

2025-10-14

·PRNewswire

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of three studies at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. All three studies highlight how Lunit's AI pathology solution, Lunit SCOPE IO®, can identify biomarkers that predict response to immune checkpoint inhibitors (ICIs), offering new potential to guide more effective and personalized cancer treatment. Among these, the first study, selected for oral presentation, was conducted in collaboration with Chiara Cremolini, MD, PhD, Professor of Medical Oncology at the University of Pisa, Italy. Researchers applied Lunit SCOPE IO to pre-treatment H&E slides from patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) enrolled in the AtezoTRIBE and AVETRIC trials. The AI quantified multiple cell types within the tumor microenvironment, generating a biomarker that stratified patients into "biomarker-high" and "biomarker-low" groups. In the AtezoTRIBE trial, biomarker-high patients treated with atezolizumab plus FOLFOXIRI/bevacizumab showed significantly improved progression-free survival (PFS) and overall survival (OS) compared to biomarker-low patients, while no such benefit was observed in the control arm. Validation in the AVETRIC cohort confirmed improved survival outcomes for biomarker-high patients receiving ICI-based therapy, with better PFS and OS compared to biomarker-low patients. These results suggest that an AI-derived tumor microenvironment biomarker could help identify patients with pMMR mCRC who are most likely to benefit from immunotherapy combinations—an urgent unmet need in this population. A collaborative study with Yonsei University College of Medicine, Korea, evaluated whether AI-defined immune phenotypes (IP) could predict outcomes in patients with advanced clear cell renal cell carcinoma (ccRCC) treated with either nivolumab plus ipilimumab (NIVO+IPI) or sunitinib (SUN). Using Lunit SCOPE IO, tumors were classified as inflamed or non-inflamed, based on the density and spatial distribution of tumor-infiltrating lymphocytes. Patients with inflamed tumors treated with NIVO+IPI demonstrated significantly longer PFS, OS, and higher response rates (60.5% vs. 23.2%) compared to those with non-inflamed tumors. No such benefit was observed in the SUN arm. Findings were validated in an independent ccRCC cohort and aligned with inflamed gene expression signatures from The Cancer Genome Atlas, supporting AI-based immune phenotyping as a promising biomarker to guide treatment selection between immunotherapy combinations and targeted therapies in first-line treatment for ccRCC. The third study, conducted in collaboration with the National Cancer Center Hospital East (NCCHE) Japan, further validated the predictive power of Lunit SCOPE IO for ICI treatment response in non-small cell lung cancer (NSCLC) patients. In this multicenter prospective study, tumors classified as inflamed showed significantly better responses and longer survival with ICI therapy compared to non-inflamed tumors, a difference not observed among patients treated with cytotoxic chemotherapy. This result strengthens the evidence supporting Lunit SCOPE IO as a predictive biomarker for immunotherapy benefit in NSCLC. "At ESMO 2025, we are demonstrating how AI can unlock predictive biomarkers directly from routine pathology slides," said Brandon Suh, CEO of Lunit. "These findings show the potential of Lunit SCOPE IO to help identify patients who will truly benefit from immunotherapy—whether in colorectal or kidney cancer—and to guide treatment strategies that can make cancer care more precise and effective." Lunit's Featured Presentations at ESMO 2025 Oral Presentation [#725O/Berlin Auditorium - Hub 27, Oct.20, 09:10-20 AM]: Leveraging Artificial Intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: translational analyses of AtezoTRIBE and AVETRIC trials — Chiara Cremolini, University of Pisa, Italy Poster Presentation [#1912P]: Inflamed immune phenotype as a novel predictive marker of immune checkpoint inhibitors for non-small cell lung cancer — Yoshitaka Zenke, National Cancer Center Hospital East, Japan Poster Presentation [#2624P]: Artificial intelligence (AI)-powered immune phenotype predicts differential benefit from nivolumab plus ipilimumab versus sunitinib in advanced clear cell renal cell carcinoma — Chang Gon Kim, Yonsei University College of Medicine, Korea Visit Lunit at booth #3017 to learn more about its latest AI-powered cancer research and innovations in digital pathology. ### About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 7,000 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io. SOURCE Lunit WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

免疫疗法临床研究

2025-10-14

·阿斯利康中国

阿斯利康携四项重磅研究首发数据亮相欧洲肿瘤内科学会（ESMO）年会，进一步彰显重新定义癌症治疗的雄心

● DESTINY-Breast11与DESTINY-Breast05两项研究入选主席研讨会（Presidential Symposium），凸显德曲妥珠单抗在治疗HER2阳性早期乳腺癌中的潜在价值 ● TROPION-Breast02研究数据将展示德达博妥单抗在转移性三阴性乳腺癌这一最具侵袭性的乳腺癌分型中的治疗潜力 ● POTOMAC研究的无病生存期数据与MATTERHORN研究的生存期数据将展示度伐利尤单抗在早期膀胱癌与胃癌治疗中的获益重磅发布 2025年10月14日，上海——阿斯利康将于2025年10月17日至21日召开的欧洲肿瘤内科学会（ESMO）年会上，凭借行业领先的多样化产品与管线布局的全新研究数据，进一步彰显其重新定义癌症治疗格局的雄心壮志。本次大会上，阿斯利康将公布逾95项摘要，涵盖9款已获得批准药物及9款潜在新药，包括2项入选重磅主席研讨会（Presidential Symposium）的摘要以及26项口头报告。其中主要亮点包括： DESTINY-Breast11：评估德曲妥珠单抗序贯THP方案（紫杉醇、曲妥珠单抗及帕妥珠单抗）用于高风险HER2阳性早期乳腺癌新辅助治疗的III期临床研究（主席研讨会1，摘要#291O）。 DESTINY-Breast05：评估德曲妥珠单抗用于HER2阳性早期乳腺癌（新辅助治疗后存在残留浸润病灶并具有高复发风险）的III期临床研究（主席研讨会1，摘要#LBA1）。 TROPION-Breast02：评估德达博妥单抗用于一线治疗无法接受免疫治疗的局部复发性不可手术或转移性三阴性乳腺癌（TNBC）患者的III期临床研究（优选论文摘要#LBA21）。 POTOMAC：评估度伐利尤单抗联合卡介苗（BCG）诱导与维持治疗，用于高危非肌层浸润性膀胱癌（NMIBC）患者的III期临床研究（优选论文摘要#LBA108）。 MATTERHORN：公布III期临床研究的最终总生存期（OS）结果，评估度伐利尤单抗联合FLOT化疗作为可切除的早期和局部晚期的胃和胃⻝管结合部腺癌（GEJ）患者围手术期治疗中的临床获益（优选论文摘要#LBA81）。高书璨(Susan Galbraith) 阿斯利康全球执行副总裁全球肿瘤研发负责人我们正加速推进多元创新疗法管线，以变革乳腺癌患者的治疗格局。在本届ESMO大会上，我们将公布TROPION-Breast02、DESTINY-Breast11和DESTINY-Breast05研究的数据和重要进展。同时，我们也将展示新一代潜在抗肿瘤新药的数据，包括saruparib联合新型激素疗法用于前列腺癌领域，靶向叶酸受体的抗体偶联药物torvu-sam用于卵巢癌领域，以及rilvegostomig用于在非小细胞肺癌领域。 Dave Fredrickson 阿斯利康全球执行副总裁肿瘤业务负责人我们业界领先的肿瘤产品组合在本次ESMO持续展现强劲势头，首次公布了四项关键研究的数据。其中，不仅有德曲妥珠单抗和德达博妥单抗在乳腺癌领域的重大进展，度伐利尤单抗的POTOMAC试验结果也证明了免疫疗法为早期膀胱癌治疗带来的益处，进而阐释我们的策略——将前沿治疗引入癌症早期这一患者最能够获益的阶段。其它亮点包括： FONTANA：评估靶向叶酸受体α（FRα）的抗体药物偶联物AZD5335用于铂耐药复发性卵巢癌患者的I/IIa期首次人体临床试验（简短口头报告摘要#1065MO）。 PETRANHA：评估saruparib联合雄激素受体通路抑制剂用于治疗转移性前列腺癌患者的I/II期临床研究（简短口头报告摘要#2384MO）。 ARTEMIDE-01：评估rilvegostomig用于检查点抑制剂初治的转移性非小细胞肺癌（NSCLC）患者的I/II期临床研究（简短口头报告摘要#1853MO）。 FLAURA2：在奥希替尼合化疗治疗晚期EGFR突变NSCLC患者的FLAURA2 III期临床研究中存在不良预后因素患者的探索性OS分析（优选论文摘要#LBA77）。 CAPItello-281：卡匹色替联合阿比特龙和雄激素剥夺疗法（ADT）用于PTEN缺陷的新发转移性激素敏感性前列腺癌（mHSPC）的III期临床研究（优选论文摘要#2383O）。 TROPION-PanTumor03：评估德达博妥单抗联合rilvegostomig治疗局晚期或转移性尿路上皮癌（a/mUC）患者的疗效： II期TROPION-PanTumor03研究结果结果（简短口头报告摘要 #3072MO）。 BEGONIA：德达博妥单抗联合度伐利尤单抗用于既往未经治疗的不可切除、局部晚期或转移性三阴性乳腺癌（TNBC）患者的BEGONIA Ib/II期试验最终结果（口头报告摘要#555MO）。阿斯利康与第⼀三共联合开发和商业化德曲妥珠单抗与德达博妥单抗；与默沙东（默沙东是美国新泽⻄州罗威市默克公司的公司商号）联合开发和商业化奥拉帕利；与和黄医药合作开发和商业化赛沃替尼。Rilvegostomig是一种靶向PD-1和TIGIT的双特异性抗体，其中TIGIT部分源自Compugen公司临床阶段的抗TIGIT抗体COM902。阿斯利康在2025年 ESMO年会期间的重要演讲1 主要作者摘要标题报告详情(CEST) 抗体偶联药物 Harbeck, N DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Abstract #291O Presidential 1 18 October 2025 4:30 PM Geyer, C Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. Abstract #LBA1 Presidential 1 18 October 2025 4:52 PM Dent, R. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Abstract #LBA21 Proffered Paper Session 19 October 2025 9:25 AM Loibl, S Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for patients with HER2+ advanced/metastatic breast cancer: additional analysis of DESTINY-Breast09 in key subgroups of interest. Abstract #LBA18 Proffered Paper Session 19 October 2025 8:30 AM Rha, SY Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase 2 TROPION-PanTumor03 study. Abstract #3072MO Mini Oral Session 17 October 2025 4:10 PM Oaknin, A First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer. Abstract #1065MO Mini Oral Session 19 October 2025 10:53 AM Schmid, P Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase 1b/2 BEGONIA study. Abstract #555MO Mini Oral Session 20 October 2025 10:50 AM Raghav, K Trastuzumab deruxtecan (T DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase 2 trial. Abstract #737P Poster Session Peng, Z Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06) Abstract #2105P Poster Session Shen, L Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in the DESTINY-Gastric06 (DG-06) trial. Abstract #2175P Poster Session Pietrantonio, F Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04 (DG-04). Abstract #2099P Poster Session Makker, V Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 1 final analysis. Abstract #957P Poster Session Lee, J-Y Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. Abstract #145P Poster Session 免疫肿瘤学 Tabernero, J MATTERHORN Phase III trial of Imfinzi (durvalumab) perioperative Imfinzi (durvalumab) plus FLOT chemotherapy in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. Abstract #LBA81 Proffered Paper Session 17 October 2025 2:00 PM De Santis, M Durvalumab (D) in Combination with Bacillus Calmette-Guérin (BCG) for BCG-naïve, High-risk Non-muscle-invasive Bladder Cancer (NMIBC): Results from the Phase 3, Open-label, Randomised POTOMAC Trial. Abstract #LBA108 Proffered Paper Session 17 October 2025 2:10 PM Larkin, J First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Abstract #LBA93 Proffered Paper Session 18 October 2025 9:20 AM Aghajanian, C Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025. Abstract #LBA44 Mini Oral Session 19 October 2025 11:31 AM Goss, G CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): final overall survival (OS) and minimal residual disease (MRD) analyses. Abstract #LBA68 Mini Oral Session 20 October 2025 3:20 PM Heymach, J Association of radiomic features ± on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN。 Abstract #LBA70 Mini Oral Session 20 October 2025 3:50 PM Wermke, M Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study. Abstract #2757O Proffered Paper Session 18 October 2025 8:30 AM Loibl, S Durvalumab in Combination with Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) – Long-term Analysis from the GeparNuevo Trial. Abstract #292MO Mini Oral Session 19 October 2025 10:15 AM Van der Heijden, M Health-related quality of life (HRQoL) from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC). Abstract #3069MO Mini Oral Session 17 October 2025 4:00 PM Sangro, B Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the Phase 3 HIMALAYA study. Abstract #1494P Poster Session Westin, S Durvalumab plus carboplatin/paclitaxel followed by durvalumab for endometrial cancer: Tumour mutational burden-high subpopulation efficacy analyses from the DUO-E trial. Abstract #1117P Poster Session Leal, TA Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC. Abstract #1794P Poster Session Reck, M Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study. Abstract #LBA65 Proffered Paper Session 18 October 2025 9:15 AM Maruki, Y CELEBRATE Study (JCOG2107E): A Multicenter, Open-label, Phase III Trial of Etoposide, Carboplatin, and Durvalumab in First-line Treatment of Unresectable or Recurrent Digestive NEC. Abstract #1734TiP Poster Session Oudard, S A phase IIIb, open-label, single-arm, global study of perioperative durvalumab (D) with neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or gemcitabine/cisplatin (gem/cis) in patients with muscle-invasive bladder cancer (MIBC) (NIAGARA-2). Abstract #3133eTiP ePoster Session 双特异性抗体 Chul Cho, B Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific Antibody, for Checkpoint Inhibitor (CPI)-Naïve Metastatic Non-Small-Cell Lung Cancer (mNSCLC): ARTEMIDE-01. Abstract #1853MO Mini Oral Session 20 October 2025 10:25 AM Slomovitz, BM A randomized Phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24. Abstract #1223TiP Poster Session Naidoo, J ARTEMIDE-Lung04: A Phase 3, randomised, double-blind, global study of rilvegostomig or pembrolizumab monotherapy as first-line (1L) treatment for patients with metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50%. Abstract #2025TiP Poster Session 肿瘤驱动因子和耐药性 Jänne, PA FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poor prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment for EGFR-mutated (EGFRm) advanced NSCLC. Abstract #LBA77 Proffered Paper Session 17 October 2025 4:56 PM Mayer, E Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC). Abstract #486MO Mini Oral Session 20 October 2025 10:25 AM Arriola, E Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC. Abstract #1817MO Mini Oral Session 20 October 2025 2:55 PM Park, YH Visual symptom questionnaire results from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1m during first-line (1L) therapy for patients (pts) with HR+/HER2- advanced breast cancer (ABC). Abstract #528P Poster Session Chu, Q SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osi. Abstract #1955P Poster Session Rotow, J MET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Interim analysis of a global real world (rw) study. Abstract #1967P Poster Session Yu, Y ctDNA analysis in phase 3 SACHI trial: Savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI). Abstract #1954P Poster Session DNA损伤应答 Azad, AA First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC). Abstract #2384MO Mini Oral Session 17 October 2025 2:35 PM Fizazi, K A Phase 3 study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Abstract #2383O Proffered Paper Session 19 October 2025 11:19 AM Rugo, HS Capivasertib with fulvestrant as first- and second-line endocrine therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPItello-291 trial. Abstract #526P Poster Session Gao, Q Final overall survival (OS) analysis of L-MOCA: olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC). Abstract #1090P Poster Session AI驱动的临床试验 Gonuguntla, HK Real-World Validation of AI-defined Lung Nodule Malignancy Score (qXR-LNMS) in Predicting Risk of Lung Cancer: Interim results from Phase 2. Abstract #2978P Poster Session 1阿斯利康在2025年ESMO年会将公布逾90个摘要，涵盖其产品和管线中的分子药物。关于阿斯利康肿瘤领域的研究阿斯利康正引领着肿瘤领域的⼀场⾰命，致⼒提供多元化的肿瘤治疗⽅案，以科学探索肿瘤领域的复杂性，发现、研发并向患者提供改变⽣命的药物。阿斯利康专注于最具挑战性的肿瘤疾病，通过持续不断的创新，阿斯利康已经建⽴了⾏业领先的多元化的产品组合和管线，持续推动医疗实践变⾰，改变患者体验。阿斯利康以期重新定义癌症治疗并在未来攻克癌症。关于阿斯利康阿斯利康（LSE/STO/Nasdaq: AZN）是⼀家科学⾄上的全球⽣物制药企业，专注于研发、⽣产及营销处⽅类药品，重点关注肿瘤、罕⻅病以及包括⼼⾎管肾脏及代谢、呼吸及免疫在内的⽣物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com。关于阿斯利康中国阿斯利康⾃1993年进⼊中国以来，专注中国患者需求最迫切的治疗领域，包括肿瘤、⼼⾎管、肾脏、代谢、呼吸、消化、罕⻅病、疫苗抗体及⾃体免疫等，已将40多款创新药物带到中国。阿斯利康中国总部位于上海，并在上海和北京设⽴全球战略研发中⼼，在北京、⼴州、杭州、成都、⻘岛设⽴区域总部，在⽆锡、泰州、⻘岛建⽴全球⽣产供应基地，向全球70多个市场输送优质创新药品。声明：本文研究中涉及的多种药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。内容来源：新闻稿（内部审批号：CN-169484）

临床3期临床成功免疫疗法临床结果

2025-10-14

·肿瘤界

STTT(IF=52.7) | 程树群教授团队为中期肝癌患者提供更优治疗选择

点击蓝字关注我们 2025年10月6日，上海东方肝胆外科医院程树群教授团队领衔的一项国际多中心II期临床试验取得重要突破，在国际著名期刊Signal Transduction and Targeted Therapy（中科院一区TOP，IF=52.7）发表最新成果，研究题为“Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial”。该研究是首个探索经动脉化疗栓塞 (TACE) 与阿替利珠单抗（免疫检查点抑制剂）/贝伐珠单抗（抗血管生成药物）序贯时机的前瞻性研究，研究结果证实了该三联方案可使中期肝细胞癌（HCC）患者的中位无进展生存期（PFS）达17.9个月，中位总生存期（OS）突破33个月，客观缓解率（ORR）提升至47%，为占肝癌总数20%-30%的中间期患者群体提供了更优治疗选择。研究亮点 △程树群教授为肝癌患者检查引流管在全球范围内，肝细胞癌 (HCC) 是第六大最常见癌症和癌症相关死亡的第三大原因，构成了巨大的公共卫生负担。根据巴塞罗那临床肝癌（BCLC）分期系统，中期HCC（BCLC B期）患者约占总数三成，传统标准治疗TACE虽能通过栓塞肿瘤供血动脉实现局部控制，但面对多结节或大体积肿瘤时疗效有限——历史数据显示其ORR仅约30%，三年生存率不足26%。反复TACE可能导致肝功能恶化，而单纯依赖局部治疗难以遏制疾病进展，约80%患者确诊时已错过手术机会，亟需更有效的综合治疗策略。 △试验概况和患者流程图 2021年8月21日-2023年4月10日，研究纳入45例HBV相关中期HCC患者，接受TACE治疗后序贯阿替利珠单抗（1200mg Q3W）+贝伐珠单抗（15mg/kg Q3W）维持治疗直至疾病进展。截至2024年9月30日数据截止，中位随访时间为26.7个月。结果显示，按RECIST标准ORR达47%（21/45），mRECIST标准ORR高达67%（30/45）。中位PFS为17.9个月，中位OS为33.0个月。疾病控制率（DCR）为87% (RECIST v1.1) /91% (mRECIST)。在45例患者中，44例出现任何级别的不良事件（AE），其中20例报告了3-4 级AE；未观察到5 级AE。总体而言，本试验提示TACE联合阿替利珠单抗与贝伐珠单抗治疗中期HCC是一种可行且耐受性良好的治疗方案。令人鼓舞的疗效和良好的安全性值得在更大的随机对照试验中进一步验证。专家简介独立通讯作者：程树群肝外六科主任，主任医师、教授专家简介：程树群教授长期从事肝癌外科综合诊治，主要研究方向是肝癌合并血管癌栓诊治及其机制研究，先后获批教育部长江学者特聘教授、国家杰出青年科学基金、国务院特殊津贴、国家百千万人才工程“有突出贡献中青年专家”、国家重点研发计划项目首席科学家、全军创新人才工程拔尖人才和上海市医学领军人才。 △程树群教授（右二）在手术中担任中国医师协会肝癌专业委员会主任委员、肝癌专业委员会青年专委会主任委员和肝癌专业委员会门静脉癌栓多学科协作专委会主任委员。在Nat Med、J Clin Oncol、Gastroenterology等期刊上发表论文200余篇。主编《肝癌门静脉癌栓治疗》，参编专著10部。获授权发明专利40余项。 △程树群教授（右）为海军基层官兵看诊以第一责任人承担国家杰出青年科学基金、国家自然科学基金重点项目、国家科技部重点研发计划等项目40余项。作为核心成员获2012年首届国家科技进步奖创新团队奖。以第一完成人获上海市科技进步奖一等奖、二等奖各1项，上海市医学科技奖二等奖1项。获吴孟超医学青年基金奖、全军育才奖银奖。声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：上海东方肝胆外科医院原标题：影响因子IF=52.7！我院程树群教授团队为中期肝癌患者提供更优治疗选择

临床结果临床2期

100 项与贝伐珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06409	贝伐珠单抗	L01XC07	DB00112

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
不可切除的肝细胞癌	日本	Chugai Pharmaceutical Co., Ltd.	2020-09-25
肝细胞癌	美国	Genentech, Inc.	2020-05-29
复发性胶质母细胞瘤	美国	Genentech, Inc.	2020-05-29
复发性原发性腹膜癌	美国	Genentech, Inc.	2014-11-14
卵巢癌	日本	Chugai Pharmaceutical Co., Ltd.	2013-11-22
胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2013-06-14
乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2011-09-26
结直肠癌	日本	Chugai Pharmaceutical Co., Ltd.	2009-09-18
转移性肾细胞癌	美国	Genentech, Inc.	2009-07-31
胶质母细胞瘤	美国	Genentech, Inc.	2009-05-05
转移性结直肠癌	美国	Genentech, Inc.	2009-05-05
节细胞神经胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2007-04-18
非鳞状非小细胞肺癌	美国	Genentech, Inc.	2006-10-11
输卵管癌	欧盟	Roche Registration GmbH	2005-01-12
输卵管癌	冰岛	Roche Registration GmbH	2005-01-12
输卵管癌	列支敦士登	Roche Registration GmbH	2005-01-12
输卵管癌	挪威	Roche Registration GmbH	2005-01-12
转移性乳腺癌	欧盟	Roche Registration GmbH	2005-01-12
转移性乳腺癌	冰岛	Roche Registration GmbH	2005-01-12
转移性乳腺癌	列支敦士登	Roche Registration GmbH	2005-01-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期子宫内膜癌	临床3期	-	National Cancer Institute	2025-12-15
复发性子宫内膜癌	临床3期	-	National Cancer Institute	2025-12-15
晚期头颈癌	临床3期	美国	National Cancer Institute	2023-03-13
头颈部皮肤鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
头颈癌转移	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽癌	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
口咽肿瘤	临床3期	美国	National Cancer Institute	2023-03-13
复发性咽部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
复发性头颈部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ChiCTR2100049829 (Pubmed) 人工标引	临床2期	肝细胞癌	45	Transarterial chemoembolization + atezolizumab + bevacizumab	夢夢壓憲醖鑰鹽選蓋鑰(鬱醖簾願壓餘窪繭餘壓) = 廠夢壓簾網鏇簾製獵構顧鬱鬱選顧積廠簾觸衊 (艱糧糧膚觸遞獵積簾齋 ) 更多	积极	2025-10-06
NCT04487067 (AMETHISTA, CTgov)	临床3期	不可切除的肝细胞癌	152	Atezolizumab+Bevacizumab	積鏇範壓鹽顧積築築淵 = 鏇簾餘廠觸壓簾襯鬱鬱壓構艱醖蓋鬱選觸艱膚 (廠衊顧鬱衊醖網蓋鏇廠, 鏇鏇淵網鑰範觸糧醖製 ~ 繭壓築繭醖襯齋構壓餘) 更多	-	2025-09-22
NEWS 人工标引	临床2期	非鳞状非小细胞肺癌	-	斯鲁利单抗+贝伐珠单抗+培美曲塞+卡铂	網網製齋構獵壓膚築積(齋願襯淵壓鹽網簾鹽鹹) = 繭顧窪憲構鬱鏇鹽繭範選憲選構夢齋壓齋糧鹽 (鑰淵淵選憲淵簾簾範繭 ) 更多	积极	2025-09-10
NCT04958811 (WCLC2025)	临床2期	鳞状细胞肺癌二线 PDL1 TPS ≥1%	12	bevacizumab+Atezolizumab+Tiragolumab	艱艱鏇齋選築鑰衊觸憲(襯淵衊選齋齋鹹築網襯) = 簾鏇夢餘廠膚蓋餘淵壓鹽衊顧鑰膚衊遞餘艱膚 (蓋夢膚鹹窪淵齋範淵齋 ) 更多	积极	2025-09-07
EURETINA2025	N/A	葡萄膜脑膜脑炎综合征	9	Ranibizumab	壓淵觸壓齋築壓願艱蓋(願簾夢簾顧繭製鬱窪構) = 鑰鬱窪蓋艱遞衊範製繭襯鬱餘壓憲蓋網廠繭襯 (齋壓獵簾廠積觸顧衊夢 ) 更多	积极	2025-09-04
NCT02681549 (Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases, CTgov)	临床2期	非小细胞肺癌 \| 转移性黑色素瘤 \| 鳞状非小细胞肺癌 ... 更多	41	Pembrolizumab+Bevacizumab (Untreated Brain Metastases From Melanoma)	製遞襯選築鹹遞積網鑰 = 繭鹽憲憲願鹹夢遞鏇簾觸遞醖蓋繭糧觸糧窪壓 (齋網範遞構窪艱範憲艱, 構鹹觸淵膚網觸網願鏇 ~ 鑰繭製糧鏇簾繭觸簾構) 更多	-	2025-08-07
	临床2期	非小细胞肺癌 \| 转移性黑色素瘤 \| 鳞状非小细胞肺癌 ... 更多	41	Pembrolizumab+Bevacizumab (Untreated Brain Metastases From NSCLC)	製遞襯選築鹹遞積網鑰 = 願鬱憲積鏇範壓獵餘觸觸遞醖蓋繭糧觸糧窪壓 (齋網範遞構窪艱範憲艱, 憲鹽艱壓艱築憲築願艱 ~ 顧觸築製選廠憲鏇鹽構) 更多	-	2025-08-07
NCT05357417 (U-BOMB, Pubmed \| JAMA Oncol) 人工标引	临床2期	转移性HER2阴性乳腺癌 HER2/Neu Negative	47	Utidelone +Bevacizumab	廠齋鏇鏇鏇鏇鹽網獵鹽(鑰蓋遞鏇繭廠膚齋構築) = 積築窪窪築糧醖蓋構餘鹹淵鏇夢構鹽構鬱獵願 (鹽簾窪壓餘鬱衊艱膚繭, 28.3 ~ 57.8) 更多	积极	2025-08-01
DUBHE-L-201 (Pubmed \| J Hematol Oncol) 人工标引	临床2期	EGFR突变的非小细胞肺癌 EGFR Mutation	31	Iparomlimab and tuvonralimab (QL1706) + Bevacizumab + Chemotherapy (cohort 5)	選選願醖鹽夢範衊糧選(顧膚繭獵築願繭齋壓簾) = 鬱鏇壓夢範衊艱構獵築構餘範鑰夢齋膚憲鬱積 (襯鏇構夢齋繭膚夢簾窪, 12.81 ~ NR) 更多	积极	2025-07-26
DUBHE-L-201 (Pubmed \| J Hematol Oncol) 人工标引	临床2期	EGFR突变的非小细胞肺癌 EGFR Mutation	31	Iparomlimab and tuvonralimab (QL1706) + Bevacizumab + Chemotherapy (21L858R mutation + cohort 5)	選選願醖鹽夢範衊糧選(顧膚繭獵築願繭齋壓簾) = 顧憲夢鑰淵齋願壓淵糧構餘範鑰夢齋膚憲鬱積 (襯鏇構夢齋繭膚夢簾窪 ) 更多	积极	2025-07-26
NCT03574779 (OPAL Phase II Trial \| OPAL, CTgov)	临床2期	卵巢癌	77	Niraparib+Bevacizumab+Dostarlimab (Cohort A (Dostarlimab + Bevacizumab + Niraparib))	製觸觸範顧夢願選築築 = 糧淵鬱遞蓋築鹽鬱範製壓觸顧鬱構遞糧網鑰膚 (網簾積鏇鹹鏇襯構鹽鬱, 網範艱築夢襯廠醖鹹鏇 ~ 範齋襯鹽鑰餘鬱構選鬱) 更多	-	2025-07-15
NCT03574779 (OPAL Phase II Trial \| OPAL, CTgov)	临床2期	卵巢癌	77	taxane+Niraparib (Cohort C (Niraparib OR Platinum-taxane))	製觸觸範顧夢願選築築 = 網繭廠餘淵襯艱觸衊獵壓觸顧鬱構遞糧網鑰膚 (網簾積鏇鹹鏇襯構鹽鬱, 遞襯壓積製簾顧構餘繭 ~ 範鹹顧觸淵餘糧簾鹽鹽) 更多	-	2025-07-15
NCT04712643 (TALENTACE, NEWS \| ASCO_GI2025) 人工标引	临床3期	不能切除的恶性肝癌	342	TACE+阿替利珠单抗+贝伐珠单抗	顧獵鹽艱蓋遞製蓋鹽簾(窪衊鏇築積築夢衊衊廠) = 範糧窪餘鑰艱鬱鏇衊簾獵廠繭顧廠醖繭獵窪夢 (夢顧網願鑰簾構壓網製 ) 更多	积极	2025-07-04
NCT04712643 (TALENTACE, NEWS \| ASCO_GI2025) 人工标引	临床3期	不能切除的恶性肝癌	342	单独TACE	顧獵鹽艱蓋遞製蓋鹽簾(窪衊鏇築積築夢衊衊廠) = 網築醖繭糧範鏇襯選鏇獵廠繭顧廠醖繭獵窪夢 (夢顧網願鑰簾構壓網製 ) 更多	积极	2025-07-04